IPC
ENTA icon

Independent Portfolio Consultants’s Enanta Pharmaceuticals ENTA Stock Holding History

Independent Portfolio Consultants’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-445
Closed -$15K – 832
2016
Q4 		$15K Sell
445
-180
-29% -$5.16K ﹤0.01% 658
2016
Q3 		$17K Sell
625
-45
-7% -$1.04K 0.01% 637
2016
Q2 		$15K Hold
670
– – ﹤0.01% 668
2016
Q1 		$20K Hold
670
– – 0.01% 663
2015
Q4 		$22K Hold
670
– – 0.01% 670
2015
Q3 		$24K Buy
+670
New +$28.8K 0.01% 667

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
MCM
Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Independent Portfolio Consultants's ENTA Position: Q1 2017 in Review

Independent Portfolio Consultants sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 445 shares — an estimated $15K sold.

Independent Portfolio Consultants first reported a position in ENTA in Q3 2015 and held it in 6 quarters. The position peaked at $24K in Q3 2015. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

  • Independent Portfolio Consultants reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Independent Portfolio Consultants sold 445 Enanta Pharmaceuticals shares in Q1 2017, an estimated $15K.
  • Independent Portfolio Consultants first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 6 quarters.
  • Independent Portfolio Consultants's Enanta Pharmaceuticals position peaked at $24K in Q3 2015.
  • 126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Independent Portfolio Consultants's 13F filing for Q1 2017, filed 25 Apr 2017.